Seroba, a leading venture capital firm based in Dublin and specializing in life sciences, has successfully closed its fourth fund, Seroba Fund IV, with a total capital of €123 million.
This new fund is set to make a significant impact in the life sciences sector, with plans to invest in up to 12 companies. Already, investments have been made in five promising companies, including Perfuze, Sibylla Biotech, Deciphex, Complement Therapeutics, and Artica Therapeutics, each dedicated to addressing critical medical needs.
Advertisement
Targeting Early-Stage Life Sciences Innovations
Seroba Fund IV is strategically focused on early-stage investments within the life sciences domain, with a geographical focus on Western Europe and selective investments in North America. The fund is particularly interested in biotech innovations, aiming to support ventures from their nascent stages of development.
Broad Investor Support
The fund has garnered support from a mix of returning and new investors, demonstrating strong confidence in Seroba’s strategy and team. Notable backers include the European Investment Fund (EIF), the Ireland Strategic Investment Fund (ISIF), Enterprise Ireland (EI), and Allied Irish Banks (AIB). New investors have also joined the fold, including CDP Venture Capital from the U.S. and several family offices, enhancing the diversity and strength of the fund’s investor base.
Bruno Montanari, a partner at Seroba, expressed gratitude for the trust placed in the firm by both existing and new investors, emphasizing the team’s commitment to investing in breakthrough medical solutions.
Seroba’s Vision for Life Sciences
With operations in Dublin, Paris, and Milan, Seroba stands at the forefront of biotech and medtech innovation. The firm’s fourth fund underscores its commitment to transforming patient treatment and addressing unmet medical needs, thereby creating significant value. Seroba’s team, leveraging extensive industry expertise, collaborates closely with entrepreneurs and investors alike to advance human health and achieve financial success.
To date, the VC has invested in thirty-two life sciences companies, introducing twenty new medical devices and eight new therapeutics to the market. The firm’s pan-European presence and strategic focus areas position it to evaluate and capitalize on a robust pipeline of investment opportunities.
Alan O’Connell, another partner at Seroba, highlighted the attractiveness of the life sciences sector for investors, citing the rapid pace of innovation and the high quality of investment opportunities currently available. He emphasized the industry’s potential to improve healthcare standards and extend human life, all while delivering strong returns to investors.
The successful closure of Fund IV at €123 million marks a significant milestone in the VC’s mission to drive innovation and investment in the life sciences sector, promising to bring groundbreaking medical solutions to the forefront.
